Vaughn, David W.
GlaxoSmithKline (United States)
2 papers on CoChatORCID 0000-0002-1396-1690
Most cited papers
- Verified
Differing Influences of Virus Burden and Immune Activation on Disease Severity in Secondary Dengue‐3 Virus Infections
Libraty, D. H., Endy, T. P., Houng, H. H., Green, S., Kalayanarooj, S., Suntayakorn, S., Chansiriwongs, W., Vaughn, D. W., Nisalak, A., Ennis, F. A., et al. (2002) · The Journal of Infectious Diseases
Mosquito-borne diseases and controlViral Infections and Vectors
Cited by 494
- Verified
Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study
Kim, J. H., Drame, M., Puthanakit, T., Chiu, N.-C., Supparatpinyo, K., Huang, L.-M., Chiu, C.-H., Chen, P.-Y., Hwang, K.-P., Danier, J., et al. (2021) · Pediatric Infectious Disease Journal
Influenza Virus Research StudiesBacterial Infections and Vaccines
Cited by 14
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free